Clinical Trials Browser

Completed × spartalizumab × Lymphoid × Clear all

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT03311412 2023-05-30

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Phase 1 Completed

89 enrolled

Lymphoid

Lymphoma, Neoplasm Metastasis

NCT03365791 2022-05-27

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Phase 2 Completed

76 enrolled 14 charts

GastrointestinalLymphoidSarcomaThoracic

Adenocarcinoma Of Esophagus, Lymphoma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Small Cell Lung Carcinoma

NCT02677155 2021-03-01

Lymvac-2

Phase 2 Completed

10 enrolled

Lymphoid

Lymphoma, Follicular

NCT02740270 2021-02-21

Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas

Phase 1 Completed

92 enrolled

Lymphoid

Lymphoma

Clinical Trials

IT-01

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Lymvac-2

Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas